Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly has unveiled a $2.5 billion ... having previously been working on LOXO-783, a drug it acquired as part of its $8 billion takeover of Loxo Oncology in 2019, but jettisoned last year ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

In a phase 2 study, treatment with the oral GLP-1 drug reduced patients' weight by 14.7% after just 36 weeks. In addition to diabetes and weight loss treatments, Eli Lilly is a big player in the ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

However, Eli Lilly recently surprised investors ... as it has several new drugs to treat conditions like cancer, ulcerative colitis, and Alzheimer's disease. If Lilly is correct in its assessment ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Eli Lilly is experiencing explosive growth thanks ... According to data compiled by Coherent Market Insights, the global oncology drug market is expected to be worth $533 billion by 2031 ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly ... in the oncology market, Lilly also recently announced that it is acquiring a clinical stage drug known as ...